- Home
- INFU vs LYEL Comparison
INFU vs LYEL Comparison
Compare INFU & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INFU
- LYEL
- Stock Information
- Founded
- INFU 2005
- LYEL 2018
- Country
- INFU United States
- LYEL United States
- Employees
- INFU N/A
- LYEL N/A
- Industry
- INFU Medical/Dental Instruments
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- INFU Health Care
- LYEL Health Care
- Exchange
- INFU Nasdaq
- LYEL Nasdaq
- Market Cap
- INFU 180.4M
- LYEL 207.7M
- IPO Year
- INFU N/A
- LYEL 2021
- Fundamental
- Price
- INFU $9.99
- LYEL $12.82
- Analyst Decision
- INFU Strong Buy
- LYEL Sell
- Analyst Count
- INFU 1
- LYEL 2
- Target Price
- INFU $12.00
- LYEL $15.00
- AVG Volume (30 Days)
- INFU 289.6K
- LYEL 24.3K
- Earning Date
- INFU 11-06-2025
- LYEL 11-06-2025
- Dividend Yield
- INFU N/A
- LYEL N/A
- EPS Growth
- INFU 2168.02
- LYEL N/A
- EPS
- INFU 0.24
- LYEL N/A
- Revenue
- INFU $139,886,000.00
- LYEL $60,000.00
- Revenue This Year
- INFU $9.07
- LYEL N/A
- Revenue Next Year
- INFU $6.55
- LYEL N/A
- P/E Ratio
- INFU $42.43
- LYEL N/A
- Revenue Growth
- INFU 8.13
- LYEL 11.11
- 52 Week Low
- INFU $4.61
- LYEL $7.65
- 52 Week High
- INFU $11.04
- LYEL $32.00
- Technical
- Relative Strength Index (RSI)
- INFU 60.33
- LYEL 64.71
- Support Level
- INFU $9.90
- LYEL $12.59
- Resistance Level
- INFU $10.57
- LYEL $13.50
- Average True Range (ATR)
- INFU 0.39
- LYEL 0.67
- MACD
- INFU -0.18
- LYEL 0.18
- Stochastic Oscillator
- INFU 27.59
- LYEL 76.87
About INFU InfuSystems Holdings Inc.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.